https://www.businesswire.com/news/home/20200909005043/en/Apros-Therapeutics-Announces-IND-Clearance-from-U.S.-FDA-to-Initiate-the-Trial-of-APR003-an-Orally-Administered-GastrointestinalLiver-Targeted-TLR7-Agonist-for-Treatment-of-Advanced-Colorectal-Cancer-CRC-with-Malignant-Liver-Lesions
Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an...
Apros Therapeutics, Inc., a drug discovery and development company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of cance...
https://www.businesswire.com/news/home/20221106005001/en/Apros-Therapeutics-to-Present-Interim-Clinical-Data-from-a-Phase-1-Study-Evaluating-APR003-at-the-2022-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting-and-World-Vaccine-Immunotherapy-Congress-WVIC-West-Coast
Apros Therapeutics to Present Interim Clinical Data from a Phase 1 Study Evaluating APR003 at the...
Apros Therapeutics, Inc., a clinical stage biotechnology company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of advance...